Oculus Innovative Sciences, Inc. is a commercial healthcare company that designs, produces, and markets safe drugs, devices, and nutritional products. The Company's primary focus is on its technology platform called Microcyn Technology. This technology is based on electrically charged oxychlorine small molecules designed to target a range of organisms that cause disease (pathogens). These include viruses, fungi, spores and antibiotic-resistant strains of bacteria, such as methicillin-resistant Staphylococcus aureus, or MRSA, and vancomycin-resistant Enterococcus (VRE), in wounds, as well as Clostridium difficile (C. diff). Several Microcyn Technology tissue care products are designed to treat infections and enhance healing while reducing the need for antibiotics. The Company has two principal subsidiaries: Oculus Technologies of Mexico, S.A. de C.V. and Oculus Innovative Sciences Netherlands, B.V.